AMENDMENT NUMBER 1 TO THE COLLABORATION AND LICENSE AGREEMENT The Collaboration and License Agreement • February 22nd, 2023 • Genmab a/S • Pharmaceutical preparations
This AMENDMENT NUMBER 1 TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) made as of 8 November, 2022 (the “Amendment No. 1 Effective Date”) by and between Genmab A/S, CVR No. 2102 3884, a Danish corporation having its principal office at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark (“Genmab”) and AbbVie Biotechnology Ltd., a corporation organized under the laws of Bermuda, having a place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”), amends the Collaboration and License Agreement between Genmab and AbbVie dated as of June 10, 2020. Genmab and AbbVie are each referred to herein individually as “Party” and collectively “Parties”.
AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENTThe Collaboration and License Agreement • November 10th, 2005 • Cytokinetics Inc • Pharmaceutical preparations • New York
This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is made effective as of September 21, 2005 (the “Amendment Effective Date”) by and between Cytokinetics, Inc., a Delaware corporation (“CK”) and Glaxo Group Limited, a GlaxoSmithKline company, a United Kingdom corporation (“GSK”) (each of CK and GSK a “Party,” together the “Parties”).
AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENTThe Collaboration and License Agreement • November 15th, 2004 • Memory Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (“Amendment”) is executed to be effective this 6th day of August 2004, by and between Memory Pharmaceuticals Corporation (“Memory”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, “Roche”).
SECOND AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENTThe Collaboration and License Agreement • August 19th, 2005 • Memory Pharmaceuticals Corp • Pharmaceutical preparations
This SECOND AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this “Second Amendment”) is executed to be effective this 18th day of August 2005, by and between Memory Pharmaceuticals Corp. (“Memory”), and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”) (Memory and Roche are hereinafter referred to individually as a “Party” and collectively as the “Parties”). All capitalized terms used herein and not defined shall have the meanings set forth in the Agreement (as defined below).
